orelabrutinib
innocare,biogen
['orelabrutinib']
congress #esmo22 | mingyue wang at guangxi medical university presented outcomes of orelabrutinib+rchop in previously untreated non-gcb dlbcl patients with extranodal disease. median follow-up: 11 months, orr: 86.4%, pd: 13.6%, median pfs: not reached #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm